

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

THE GRANT OF EXCLUSIVE COMMERCIALIZATION RIGHTS TO NHWA FOR THREE LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN THE CHINESE MAINLAND

The board of directors (the “**Board**”) of Luye Pharma Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that certain subsidiaries of the Group have entered into an agreement (the “**Agreement**”) with Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., Ltd., a subsidiary of Jiangsu Nhwa Pharmaceutical Co., Ltd. (“**Nhwa**”), granting Nhwa the exclusive rights to commercialize three long-acting injectable (“**LAI**”) antipsychotics in the Chinese Mainland. The three products are Rykindo (risperidone microspheres for injection (II)), Ruibailai (paliperidone palmitate injection (II)), and Meibirui (paliperidone palmitate injection), all indicated for the treatment of schizophrenia.

Under the Agreement, Nhwa will be exclusively responsible for the distribution and commercialization of Rykindo, Ruibailai, and Meibirui in the Chinese Mainland, with the Group retaining ownership of the products’ assets, marketing authorizations, and all related intellectual property rights while remaining responsible for their manufacture and supply. The term of the Agreement is ten years. Upon the signing of the Agreement, Nhwa will pay a one-time, non-refundable licensing fee of USD 20 million to the Group. This collaboration marks the alliance of two leading players in China’s central nervous system (“**CNS**”) therapeutic field to deepen their presence in the schizophrenia treatment market and provide patients with more comprehensive treatment options.

Schizophrenia is a chronic disease with high rates of relapse and disability. Relapse due to treatment interruption or self-directed dose reduction, even progressing to treatment-resistant schizophrenia, is a major challenge in the current treatment of the disease. Compared with oral formulations, LAI antipsychotics can significantly improve treatment adherence and represent an important strategy for relapse prevention. In China, there are approximately 8 million individuals living with schizophrenia, and community healthcare institutions play a primary role in providing consolidation and maintenance treatment.

Rykindo, Ruibailai, and Meibirui were developed by the Group using its Long-Acting and Extended-Release Platform. Rykindo contains risperidone and is China's first domestically developed, innovative second-generation LAI antipsychotic. Both Ruibailai and Meibirui contain paliperidone palmitate. Ruibailai is the world's first and only once-monthly LAI paliperidone with an initiation regimen requiring only one injection in the first month.

Nhwa is a leading specialty pharmaceutical company in China with a strong focus on the CNS field. It is dedicated to building comprehensive, integrated solutions for the treatment of psychiatric and neurological disorders while fostering an end-to-end ecosystem for the diagnosis and treatment of CNS diseases. In addition to its broad CNS portfolio, Nhwa has established a large, specialized commercial organization of more than 2,000 professionals and a nationwide commercialization network covering more than 10,000 hospitals across China. Through this extensive infrastructure, Nhwa delivers its psychiatric and neurological products to mental health institutions at all levels, primary-level healthcare institutions, private hospitals, online pharmacies, and retail pharmacy chains.

The Board believes that the Group's three LAI products form a differentiated portfolio that addresses the treatment needs across all stages of schizophrenia care and has significant clinical value. CNS is one of the Group's core strategic areas. The Group has built one of the most competitive CNS portfolios in China, supported by its strong platform capabilities. By collaborating to leverage complementary resources, the Group aims to accelerate value creation across its pipeline and better address unmet clinical needs, while further prioritizing innovation and global expansion. Through this strategic partnership with Nhwa, both parties will jointly strengthen their presence in the CNS market, particularly by expanding access to these products in primary-level healthcare institutions, helping more patients receive standardized treatment and reducing disease burden.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 24 December 2025

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. HUANG Liming; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.